The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
DICERNA PHARMACEUTICALS INC COM 253031108 13,536 614,436 SH   SOLE   614,436 0 0
FATE THERAPEUTICS INC COM 31189P102 1,414 72,273 SH   SOLE   72,273 0 0
GALAPAGOS NV SPON ADR 36315X101 14,885 71,967 SH   SOLE   71,967 0 0
MERUS N V COM N5749R100 14,626 1,038,746 SH   SOLE   1,038,746 0 0
MORPHOSYS AG SPONSORED ADS 617760202 217 6,080 SH   SOLE   6,080 0 0
PIERIS PHARMACEUTICALS INC COM 720795103 17,769 4,966,820 SH   SOLE   4,966,820 0 0
PROQR THRAPEUTICS N V SHS EURO N71542109 19,053 1,922,570 SH   SOLE   1,922,570 0 0
REGENXBIO INC COM 75901B107 11,012 268,778 SH   SOLE   268,778 0 0
SPDR SERIES TRUST S&P BIOTECH 78464A870 118,888 1,250,000 SH Put SOLE   0 0 1,250,000
SPERO THERAPEUTICS INC COM 84833T103 11,099 1,154,356 SH   SOLE   1,154,356 0 0
UNIQURE NV SHS N90064101 28,442 396,899 SH   SOLE   396,899 0 0
XENON PHARMACEUTICALS INC COM 98420N105 15,296 1,166,736 SH   SOLE   1,166,736 0 0